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ABSTRACT The bovine papillomavirus type I transcrip-
tional activator E2 is essential for replication of bovine papil-
lomavirus DNA, yet most of the high-affinity binding sites for
E2 are dispensable. Here we demonstrate an absolute require-
muent for a binding site for the E2 polypeptide as a cis-acting
replication element, establishing that site-specific binding ofE2
to the origin is a prerequisite for bovine papillomavirus repli-
cation in vivo. The position and distance of the E2 binding site
relative to the other origin of replication components are
flexible, but function at a dance requires hig-affnity E2
binding sites. Thus, low-afnit binding sites function only
when located close to the origin of replication, while activity at
greater distances requires multimerized high-affinity E2 bind-
ing sites. The requirement for E2, although different in some
respects, shows distinct similarities to what has been termed
replication enhancers and may provide insight into the function
of this class of DNA replication element.
The process of initiation of DNA replication is well studied
in only a few eukaryotic systems and studies have been
largely restricted to lytic viruses due to the fact that the
necessary cis-acting elements have not been available from
other systems (1, 2). Bovine papillomavirus (BPV) is an
interesting addition to this group, because the life cycle ofthe
virus is significantly different from most well-studied viruses
(reviewed in ref. 3). It has been suggested that BPV is a
particularly good model for mammalian chromosomal DNA
replication, since the viral DNA in transformed mouse cells
is stably maintained at a constant copy number for many
generations and appears to replicate in synchrony with the
cellular DNA (4). However, in terms of replication proper-
ties-i.e., long-term stability, strict copy number control,
and low frequency of loss-the systems that most closely
resemble BPV are some prokaryotic plasmids.
We have previously demonstrated that a small noncoding
region from the BPV genome contains all the sequences
required in cis for DNA replication in vivo (5). This region is
also necessary and sufficient for replication in vitro (6). As
illustrated in Fig. 1, this short sequence contains three
recognizable elements, an A+T-rich region, a binding site for
the El polypeptide, and a binding site for the E2 polypeptide
(E2 BS12). The El and E2 polypeptides are absolutely
required in trans for replication of BPV DNA (7). The El
polypeptide is a DNA binding protein, which appears to
function as the origin of replication (Ori) recognition factor
(5, 6, 37). E2 is a site-specific DNA binding protein with
transcriptional activation properties (reviewed in ref. 8),
which has been reported to facilitate binding of El to its
binding site (6). Based on mutational analysis, we previously
concluded that E2 BS12 was of little importance for replica-
tion since mutations that reduced the ability of E2 to bind to
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FIG. 1. Ori region of BPV is depicted schematically, including
restriction sites and known elements of the Ori region. Coordinates
given are nt numbers from the BPV genome. Regions involved in
binding ofthe El and E2 polypeptides are indicated. Some ofthe Ori
constructs used in this study are indicated below. Minimal Ori
functional in vivo is also indicated. WT, wild type.
this site had little effect on DNA replication (5). As demon-
strated in this paper, however, subsequent analysis of the E2
polypeptide has indicated that specific DNA binding was
required forDNA replication and, furthermore, the ability of
E2 to support DNA replication was proportional to its DNA
binding activity. Therefore, we have reexamined the impor-
tance of the E2 binding site at the origin by a more thorough
mutational analysis. The results demonstrate that an E2
binding site is absolutely required for replication from the
BPV origin. When the E2 binding site is located close to the
other Ori elements, crippled, very low-affinity E2 binding
sites can be utilized. However, function at greater distances
requires E2 binding sites with higher affinities. These results
are consistent with a DNA-dependent interaction between
the El and E2 polypeptides where binding sites for both
proteins are required to form a functional initiation complex.
MATERIALS AND METHODS
Plasmnds. The expression vectors for the different forms of
E2 have been described (7). The point mutations in E2 were
generated by oligonucleotide-directed mutagenesis as de-
scribed (9). The HA epitope tag (10) in E2 was generated by
inserting a sequence encoding 13 amino acids from the
influenza hemagglutinin polypeptide into the E2 coding se-
quence at a Stu I site at nt 3351. All Ori constructs were
cloned into pUCl9 (Fig. 1). The Msp and Alu Ori constructs
have been described (5). The mutations in E2 BS12 were
generated in the context of the wild-type minimal Ori (nt
7914-7927), which was cloned between Xba I and HindIII in
the poly linker of pUCl9. The Msp L and Alu L plasmids, in
addition to the respective Ori fragments, contain a fragment
Abbreviations: BPV, bovine papiliomavirus; EBV, Epstein-Barr
virus.
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from the late region ofBPV between nt 4450 and 7187 cloned
into the BamHI site of pUC19. Msp/l5+BS9 contains an
oligonucleotide (E2 BS9; see below) cloned into the BamHI
site immediately upstream of the Msp/15 Ori fragment.
Msp/15+10XBS9i contains 10 copies of the same oligonu-
cleotide cloned into the BamHI site. Between theBamHI and
Xba I sites in the polylinker, a 1.0-kb spacer fragment from
the late region (nt 6132-7187) ofBPV was inserted. All point
mutations and deletions in Ori were generated by PCR using
standard protocols.
Cell Lines. Generation of the CHO cell lines 4.15 and 2.12
expressing El and E2 and the conditions for culture will be
described elsewhere (M.U. and A.S., unpublished data).
COS-7 cells were maintained in Dulbecco's modified Eagle's
medium/10% fetal bovine serum.
Electroporation and Replication Assays. All electropora-
tions and replication assays were carried out as described (7).
Fifty nanograms of Ori-containing plasmid was used in each
electroporation. Where an internal standard was cotrans-
fected, 100 ng of this larger plasmid was also used, resulting
in roughly equimolar quantities of the two plasmids. Samples
were processed as described (7) except that the cells were
treated with trypsin and resuspended at a density of 2 x 107
cells per ml. Cell suspension (0.25 ml) was mixed with DNA
and pulsed at 960 tkF, 230 V in a Bio-Rad gene pulser.
Dimerization Assay. Forty-eight hours after electropora-
tion COS cells were labeled with Tran35S-label (ICN) for 4 hr.
Extracts were prepared by lysing the cells using a buffer
containing 0.1% Nonidet P-40, 0.2 M KCl, 1 mM EDTA, 25
mM Hepes (pH 7.9). The extracts were divided into three
equal portions. Two of these were denatured with 1% SDS
diluted 1:10 and precipitated with polyclonal E2 antiserum
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and a monoclonal antibody directed against the HA epitope
(12CA5) (10), respectively. The third portion was immuno-
precipitated with 12CA5 under nondenaturing conditions.
The samples were analyzed by SDS/PAGE according to
Laemmli (11).
DNA Binding Assays. Gel-retardation assays were carried
out using an end-labeled double-stranded synthetic oligonu-
cleotide E2 BS9 (GATCTGTACCGTTGCCGGTCG). Ex-
tracts for gel retardation were prepared by lysis of the
transfected cells as described above. DNase footprint anal-
ysis was carried out as described (12) except that the buffer
used was 20 mM potassium phosphate pH 7.5/100 mM
potassium glutamate/1 mM EDTA/5 mM dithiothreitol/10%o
(vol/vol) glycerol. The probes used for footprinting were
generated by PCR amplification from the Ori plasmids with
end-labeled universal sequencing primers. Expression and
purification ofthe E2 polypeptide will be described elsewhere
(A.S. and J. Sedman, unpublished data).
RESULTS
Mutations in E2 That Affect Specific DNA Binding but Not
Dimerization Are Incapable of Supporting Replication. To
determine whether the E2 sequence-specific DNA binding
activity was required for replication of BPV-1 DNA, muta-
tions were constructed in E2 that were defective for DNA
binding but left the protein structurally intact, including the
capability to form dimers. At the time, the DNA binding and
dimerization domains had not been characterized in detail.
We therefore generated substitution mutants in three short
blocks of sequence that are conserved between E2s from
different papillomaviruses (13). Subsequently, in a thorough
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FIG. 2. (A) Mutants in the DNA binding domain of E2 are defective for DNA binding but can dimerize in vivo. Mutants were tested for
dimerization by cotransfection of the expression vectors encoding the mutant forms of E2 together with a vector encoding a short version of
E2 tagged with theHA epitope (E8/E2Epi). After transfection and metabolic labeling, cells were lysed under nondenaturing conditions. To detect
dimerization (Right), samples were immunoprecipitated with a monoclonal antibody directed against the HA epitope (HA). Immunoprecipi-
tations were performed under denaturing (D) or nondenaturing (ND) conditions. As a control, a portion of each sample was immunoprecipitated
with a polyclonal antiserum (P) under denaturing conditions. (Right) Extracts from parallel transfections were prepared and used for
gel-retardation assays with an oligonucleotide probe. (B) E2 mutants defective for DNA binding are defective for DNA replication. Ability of
the E2 mutants to support replication of an Ori plasmid was tested by electroporation of the Ori plasmid together with expression vectors
encoding the respective E2 mutants into a CHO cell line (2.12) stably expressing the El polypeptide. At the indicated times (hr), cells were
harvested and replicated DNA was measured as described. Quantitation of the blots indicated that the R -. A mutant was reduced -10-fold
in its ability to support replication, while the other three mutants were reduced "100-fold in their ability to replicate. WT, wild type.
Biochemistry: Ustav et al.
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study using a random mutagenesis approach Prakash et al.
(14) have identified a number of amino acids important for
DNA binding and dimerization and these sequences corre-
spond largely to the conserved regions. The mutants were
tested for specific DNA binding in a gel-retardation assay
with extracts from COS-7 cells transfected with expression
vectors encoding either the mutant proteins or the wild-type
form. As demonstrated in Fig. 2A, the three mutants K339A,
W360A, and R386A were all reduced in their ability to bind
to the oligonucleotide. The R386A mutant was reduced
-10-fold compared to the wild type, while the other two were
reduced at least 100-fold in their ability to bind DNA.
To determine whether these mutants were defective for
DNA binding due to an inability to dimerize and also to
determine that the proteins were expressed at similar levels,
we designed an assay to measure dimerization in vivo. We
have previously determined that shorter forms of E2 when
coexpressed with the full-length form in vivo can dimerize to
form heterodimers. Therefore, expression vectors encoding
the full-length E2 and its mutant forms, together with a short
form of E2, E8/E2Epi were cotransfected into COS cells. The
short form of E2 was tagged with a short sequence encoding
13 amino acids from the influenza hemagglutinin protein,
which is recognized by the monoclonal antibody 12CA5. After
transfection and metabolic labeling, cells were lysed under
nondenaturing conditions. To detect dimerization, samples
were immunoprecipitated with the monoclonal antibody di-
rected against the HA epitope. Under denaturing conditions,
only the tagged short form was precipitated. In contrast, under
nondenaturing conditions, the full-length form of E2 was
efficiently coprecipitated. As a control, immunoprecipitations
were carried out with a polyclonal antiserum that recognizes
both forms of E2 under denaturing conditions. As demon-
strated in Fig. 2A, the four mutants that were defective for
DNA binding were capable of dimerization in vivo. The
W360A mutant, however, was reproducibly coprecipitated
with lower efficiency than the other mutants. Furthermore, the
levels ofexpression ofeach ofthese mutants appeared similar.
To determine whether the mutant forms of E2 could support
DNA replication, the expression vectors were used in short-
term DNA replication assays. These assays were carried out
in the cell line 2.12, which is aCHO cell line that constitutively
expresses the El polypeptide. As demonstrated in Fig. 2B, in
the presence ofwild-type E2, the origin replicated to very high
levels. The mutant E2s supported replication to a varying
degree, the R389A mutant was 10-fold down, while the other
mutants were reduced =100-fold in their ability to support
replication. These results gave a clear indication that specific
DNA binding activity of the E2 protein was required for
replication. It also suggested that the ability to support repli-
cation was roughly proportional to the specific DNA binding
activity of E2.
The Affinity ofE2 for BS12 Correlates with DNA Replication
Activity. A set of mutants in E2 BS12 were constructed in the
context of the minimal Ori. Two of these mutants were
designed to increase the E2 binding affinity (PM19 and PM25)
by generating a site more similar to a strong consensus site.
One point mutation was designed to reduce the affinity of E2
(PM17) by generating a site less similar to a strong consensus
site. In addition, a deletion mutant (D22) was generated that
deleted half of the palindromic E2 BS12 binding site. When
these mutants were tested for their ability to bind E2 in a
DNase I footprint assay, it was found that the results were
consistent with the predictions-i.e., mutants PM19 and
PM25 had increased ability to bind E2, PM17 showed slightly
reduced ability to bind E2, while for D22 binding could not
be detected (Fig. 3B). When tested for their ability to repli-
cate, all these Ori mutants replicated with only minor differ-
ences in efficiency (data not shown). To provide an internal
standard in the replication assay and also possibly to enhance
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FIG. 3. A functional E2 binding site is essential for replication in
vivo. (A) A series of mutants in E2 BS12 (Lower) were tested for
replication. (Left) Constructs were cotransfected together with a
larger Ori construct Alu L into 4.15 cells expressing both El and E2
polypeptides. Lower band (arrow) represents the test plasmid and
upper band corresponds to the internal standard Alu L. (Right) Two
mutants that were replication defective (Left) were transfected alone
and shown to be replication competent in the absence of a competing
Ori. (B) DNA binding activity of mutants in E2 BS12. Ability of the
E2 polypeptide to bind to the mutant E2 binding sites was determined
by DNase footprint analysis in the absence (-) or presence of 20, 40,
or 80 ng of E2, respectively. Protected region is indicated by a bar.
Hypersensitive site is indicated by an arrow. WT, wild type.
differences due to plasmid competition, the Ori mutants
together with a larger Ori plasmid were cotransfected into the
4.15 cell line, which constitutively expresses El and E2
proteins (Fig. 3A). The Ori mutants with reduced affinity for
E2 (D22 and PM17) in this competitive situation were unable
to replicate. The mutants that were slightly increased in their
ability to bind E2 (PM19 and PM25) had increased capacity
to compete with the larger replicon compared to wild-type
Ori. As shown in Fig. 3A (Right), the two mutants D22 and
PM17 were replication competent when transfected individ-
ually in the absence of competitor.
An E2 Binding Site Is Absolutely Required for DNA Repli-
cation. These results clearly indicated that the 12 nt that
constitute E2 BS12 were important for replication and it was
suggestive that the replication competence appeared to be
related to the affinity of the binding site for E2 protein.
However, it did not prove that the E2 binding site per se was
one Biochemistry: Ustav et al.
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important. To rule out that other sequences overlapping the
BS12 were responsible for the importance of this region, we
deleted the 12 nt that constitute E2 BS12 to generate the
construct Msp/15. This plasmid was inactive for replication
both by itself and in the presence of a competing Ori (Fig. 4).
Into this construct, we inserted a different, strong E2 binding
site from the E2-dependent enhancer (E2 BS9). As demon-
strated in Fig. 4, insertion ofBS9 into the polylinker sequence
outside the minimal Ori sequence restored replication to
wild-type levels (or better), demonstrating that the replication
deficiency in Msp/15, caused by the loss of E2 BS12, could be
restored by insertion of another E2 binding site with partly
different DNA sequences. This strong E2 binding site was
functional at a position different than BS12 relative to the El
binding site.
Ability of the E2 Binding Site to Function from a Distance
Correlates with Its Affimity for E2 Protein. These results
demonstrated that an E2 binding site was an essential part of
a functional BPV Ori. Furthermore, the position and distance
of the E2 binding site relative to the El binding site did not
appear to be critical. However, a peculiar fact apparent from
the analysis of mutants in E2 BS12 was that the D22 mutant
replicated, yet binding of E2 protein could not be detected
(Fig. 3A). The sequence ACC, which is the only conserved
part of the E2 binding motif remaining in this mutant, is
obviously present in many other positions in the plasmid but
is nonfunctional at these positions. A possible explanation for
the activity of this crippled E2 binding site-could be its close
proximity to the El binding site. E2 BS9, which could
function at some distance from the El binding site, has
considerably higher affinity than BS12. To determine
whether there was a relation between the affinity of the E2
binding site and the ability to function for replication at a
distance, we generated Ori constructs where the distance
between E2 BS12 and the El binding site was increased by
inserting 3, 6, or 10 nt between the two sites. As demon-
strated in Fig. 5 (lanes 1-9), this progressively increased
distance resulted in a progressively reduced replication effi-
ciency, and +10 shows hardly detectable replication. To
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FIG. 4. A different E2 binding site at a different position can
substitute for E2 BS12. An Ori construct where the entire E2 BS12
had been deleted (Msp/15) was tested for replication in parallel with
the same construct where an oligonucleotide comprising E2 BS9 had
been inserted into the polylinker sequence (Msp/15+BS9). These
constructs were tested for replication either alone (Left) or together
with a larger internal standard (Msp/L; Right).
determine whether increasing the affinity of the binding site
for E2 protein would restore replication, we introduced the
PM25 mutation in the + 10 background. This mutation re-
stored replication to close to wild-type levels, indicating that
the increased distance could be compensated for by increased
affinity of the E2 binding site. Thus, a low-affinity site
appears to be functional only when located close to the El
binding site, while for function at greater distances higher
affinities are required. The most extreme case is the half E2
binding site that still functions for replication when located
immediately adjacent to the El binding site.
To test whether these observations were true when the E2
binding site was moved considerably further away, we in-
serted a 1.0-kb DNA sequence between E2 BS9 and the Ori
region in the Msp/15 construct. The inserted DNA fragment
was derived from the late region of BPV and contains no
known E2 binding sites. This construct failed to replicate,
indicating that even a high-affinity site was limited in its
capacity to function over large distances (data not shown).
However, when BS9 was multimerized to 10 copies and
placed at the same position, replication competence was
again restored (Fig. 5, lanes 13-15).
DISCUSSION
From a number of examples it is clear that transcriptional
elements play an important role in initiation of DNA repli-
cation. Such diverse replicons as ARS elements from Sac-
charomyces cerevisiae and the lytic polyomavirus require
transcriptional activators for initiation of DNA replication
(15-20). Polyomavirus is the best-characterized replicon in
this regard. A variety of transcription factors can activate
replication from the polyomavirus core origin. These factors
range from S. cerevisiae Gal4 and mammalian AP1 and BPV
E2 to various hybrid transactivators, such as Gal4/VP16 and
Gal4/Jun (21-25). The presence of a transcriptional activa-
tion domain appears to be an absolute requirement; the DNA
binding domain of these proteins is not sufficient (21, 25). In
contrast to their function in transcription, the sites generally
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FIG. 5. Correlation between distance and required affinity of E2
for replication activity. (Left) To determine the effect of increased
distance between the El and E2 binding sites 3, 6, or 10 nt were
inserted between the two sites in the context of the minimal Ori as
shown (Lower). In +10/25, a point mutation has been introduced at
position 25 (see Fig. 3). (Right) Replication-defective construct
Msp/15 was modified by insertion of 10 copies of E2 BS9 separated
from the Ori by a 1.0-kb spacer sequence and tested for replication.
Biochemistry: Ustav et al.
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have to be located close to the Ori and are not functional at
distances greater than 100 bp (22). In spite of this relatively
detailed information, the direct function of the transcriptional
component is not known.
It has been demonstrated that E2 can function to facilitate
the binding of El to its binding site (6). In those experiments,
no requirement for an E2 binding site was found and it was
assumed that E2 could perform this function without specific
binding to DNA. However, the E2 BS- construct that was
used in that study is the equivalent of the D22 mutant, which
retains half of the E2 binding site, which clearly is sufficient
for replication in vivo. This half palindrome is sufficient for
cooperative binding of El and E2 in vitro (J. Sedman and
A.S., unpublished data). A possible function of E2 therefore
is that binding of E2 to its binding site changes the structure
of the DNA locally, which in turn facilitates El binding. This
type of mechanism has been suggested for cooperative bind-
ing of RepA and dnaA to the plasmid R1 origin (26). This
model would be consistent with the sensitivity to slight
increases in distance observed with the low-affinity BS12.
The argument against this model is that E2 clearly can work
from a distance and also that the DNA binding domain of E2
alone is not capable of supporting replication.
A more likely explanation is that the sensitivity to distance
is a question of occupancy. If both El and E2 have low
affinity for their respective sites, these sites may need to be
close together to promote a protein-protein interaction that
stabilizes the binding of both proteins. If, on the other hand,
the E2 binding site has high affinity and is occupied a large
fraction of the time, the interaction could still take place in
spite of a greater distance between the two sites. This
scenario requires interaction between El and E2. Such an
interaction has been detected when the two proteins are
overexpressed from baculovirus vectors (27-29).
Superficially, the properties of the E2 polypeptide in
replication appear quite different from the classical replica-
tion enhancer discussed above. The requirement for E2
cannot be circumvented by addition of the polyomavirus
enhancer to the minimal Ori (M.U. and A.S., unpublished
data). The specific E2 transactivation domain is required and
cannot be replaced with the VP16 transactivation domain (5),
and E2 can function from a great distance in multimerized
form. However, at closer inspection the differences are not
as distinctive as it may seem. We have demonstrated that E2
can function either close to the Ori or at a distance from it and
that the distinction is quantitative rather than a qualitative.
For another class of replication enhancers represented by the
Epstein-Barr virus (EBV), the similarities are more obvious.
EBV encodes a protein, EBNA-1, that also doubles as a
transcriptional activator and replication factor (30-32). A
replication enhancer consisting of 20 binding sites for
EBNA-l is located 1 kb away from Ori. This enhancer is
required for replication and cannot be replaced with other
enhancers (30, 33, 34). This arrangement is virtually identical
to the requirement for multimerized E2 binding sites at a
distance for BPV replication.
An interesting way of viewing replication enhancers, based
on the results obtained with E2, is that the distance depen-
dence may reflect the strength of interaction between the
enhancer and some component in core Ori (presumably the
initiator protein). This could be the case irrespective of what
purpose the interaction is serving, either to clear nucleosomes,
which has been suggested in the case of simian virus 40 (35,
36), or to facilitate the interaction of the initiator protein with
DNA, which appears to be the case for BPV, or a combination
of the two. An intrinsically weak interaction would require
multiple sites close by, while an intrinsically strong interaction
could use either strong sites at a distance or a weak site close
by. An interesting correlation is apparent. BPV and EBV,
which both show a high degree of specificity (i.e., other
activators cannot substitute for E2 and EBNA-1), also show
high affinity based on the ability to function at a distance.
Polyomavirus can utilize many different activation domains
(low specificity) and the interactions are low affinity based on
the inability to function at a distance. One important distinc-
tion between these two types is that while core Ori of polyo-
mavirus has to be capable of interacting with various activa-
tion domains present in the cell, BPV and EBV need only
interact with their own dedicated, virus-encoded activators E2
and EBNA-1, respectively. The need to preserve the capacity
to interact with multiple activation domains may require a
compromise in terms of affinity, while BPV and EBV with one
specific partner could utilize a strong interaction.
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